Viewing nowCombinationTriploduo Controlled Release Tablet 5/1000 mg (Linagliptin, Metformin)
Linagliptin Besylate 6.67mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Mothers Pharmaceuticals Co., Ltd.

MFDS item code 202401577 · Approved 2024.06.28 · Insurance code 622805340
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication aids patients with type 2 diabetes to control their blood sugar more effectively, along with diet and exercise therapies. It is used to improve blood glucose levels with the combined action of Linagliptin and Metformin.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg (linagliptin besylate 6.67mg) and extended-release metformin hydrochloride 2000 mg. This medicine should be taken once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine equivalent to the patient's current metformin hydrochloride dose, together with a total daily dose of linagliptin 5mg, should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.
This medication is designed to assist in blood sugar control and should not be administered to certain patients. For example, individuals allergic to the ingredients contained in this medication, patients with type 1 diabetes, severe renal impairment, or those experiencing acute infections or trauma may be at risk if they use this medication. This medication can rarely cause a life-threatening condition known as lactic acidosis, so caution is particularly necessary for patients with poor kidney function, liver dysfunction, severe alcohol dependence, or acute heart disease. Symptoms of lactic acidosis include difficulty breathing, abdominal pain, and lethargy; immediate medical attention is required if these symptoms occur. There is also a risk of hypoglycemia, so if taken with other hypoglycemic agents such as insulin or sulfonylureas, blood glucose levels should be monitored frequently and dosage adjustments may be needed. Additionally, excessive exercise, skipping meals, or excessive alcohol consumption can increase the risk of hypoglycemia. This medication requires dosage adjustments based on kidney function, and elderly patients or those with decreased kidney function should be managed with extra caution. Regular blood tests to monitor kidney function are important. Use of this medication should be temporarily halted during surgery or radiological examinations, and it should be resumed only after confirming stable kidney function post-testing. This medication can cause rare side effects such as pancreatitis or skin conditions (bullous pemphigoid); in cases of severe abdominal pain, skin rashes, or blisters, immediate consultation with a physician is necessary. Long-term use of this medication can lower vitamin B12 levels, so if symptoms of anemia or neurological disturbances occur, blood tests should be performed and supplementation treatment should be initiated as necessary. This medication should be swallowed whole and not chewed or crushed, with the tablet coating potentially appearing in stool being normal. It is advisable for women who are pregnant or breastfeeding to avoid using this medication; insulin treatment is recommended for those planning a pregnancy or already pregnant. Safety and efficacy in children have not been established, and elderly patients should have dosage adjustments based on kidney function with regular monitoring of kidney function. This medication may interact with other drugs, so consultation with a physician is necessary, especially when taking medications that may affect kidney function or blood sugar. In the event of overdose, gastrointestinal disturbances or lactic acidosis may occur, requiring immediate medical treatment, which may include dialysis. Finally, this medication should be stored out of reach of children, in a moisture-free environment, and not transferred to other containers.
Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemic episodes, taste disturbance, cough, appetite loss, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigoid-like lesions, arthralgia with severity and disability, rhabdomyolysis, increased lipase, elevated amylase, constipation, epigastric pain, small bowel colitis, bowel obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, pneumonia, shortness of breath, nausea, gastroesophageal reflux disease, gastritis, headache, drowsiness, chest discomfort, asthenia, epistaxis, oropharyngeal pain, voice disorder, allergic rhinitis, exercise-induced shortness of breath, productive cough, rhinorrhea, lung mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, male pattern baldness, hyperhidrosis, hair loss, dermatitis, anxiety, mood disorders, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, thyroid enlargement, confusion, nocturia, dermatitis, hypertension
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent moisture and air exposure. The storage temperature should be maintained between 1 to 30 degrees Celsius.
This medication is a yellow oval controlled release film-coated tablet.
30 tablets/bottle, 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Besylate 6.67mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Mothers Pharmaceuticals Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
DaiWoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.